Right to Try Act Would Allow Greater Access to Experimental Treatments

Southern Maryland Online - 1 week ago
On Thursday, five and a half years...

Michelle Obama invites female Ranger grad to State of the Union

ArmyTimes.com - 4 weeks ago
Microsoft has been a leader in...

Premier discovers more high grade at McCoy-Cove

Equities.com - 3 weeks ago
Drill results from the 2015...

New wave in technology: Hacking the brain

Economic Times - 4 weeks ago
"This can be used to help...

Taking page from early AIDS activists, ALS patients push for access to experimental drug

San Francisco Business Times (blog) - 6 months ago
Ultimately, they hope to convince...

Foremay bringt SED SSD mit Datenträgerverschlüsselung und kryptographischer Löschfunktion auf den Markt

SYS-CON Media (press release) - 2 weeks ago
Der besondere Vorteil des...

Midland Completes a Soil Geochemical Survey on its Heva Gold Project and Identifies New Exploration Targets Near ...

SYS-CON Media (press release) - 2 weeks ago
For quality control, ALS Minerals...

How to Be a Devils Fan In St. Louis -- 2016 Edition

Bleeding Yankee Blue (blog) - 4 weeks ago
With the way the divisions were...

News via Google. See more news matching 'als expanded access'

 

Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.